Haematological malignancies (HM), also known as blood cancers, are a heterogeneous and complex group of multicausal diseases that can’t be easily diagnosed nor treated. Nowadays most treatments are extremely complex, and advances in patient diagnosis and therapies slow due to the low number of patients per centre. Thus, there is a need to harmonise, store, and analyse the current HM information to speed-up and support the decision-making process for patients’ access to new therapies. HARMONY PLUS takes advantage of the capabilities of the HARMONY Big Data platform to match this unmet needs by expanding its scope to incorporate myeloproliferative neoplasms, including chronic myeloid leukemia, polycythaemia vera, essential thrombocythaemia, and myelofibrosis; and lymphoproliferative disorders, including Hodgkin’s lymphoma, Waldenström macroglobulinemia and all the other rare HMs not covered by HARMONY Project. In parallel, HARMONY PLUS will continue to refine and define the Core Outcome Sets (COS), especially for these new HMs to ensure the use by researchers of useful common outcomes relevant to all stakeholders. As previously accomplished in HARMONY, HARMONY PLUS is committed to pursue the maximum ethical and legal requirements, particularly to ensure patient’s right to privacy. Data-driven research within Europe will be enhanced by converting the current HARMONY platform into an Integrated Services Platform to serve as a valuable tool to support clinical trial design and use of available data as a control arm. This platform, combined with a HaemoDatabank repository with information about HMs patient biological samples across Europe, will facilitate a more efficient research and clinical trial design, and consequently will promote collaborations with recognised databases outside Europe. From the regulatory point of view, HARMONY PLUS will be a valuable technology tool during the evaluation of new treatments and drugs by also considering the patients’ needs.

Project details

Unibo Team Leader: Gastone Castellani

Unibo involved Department/s:
Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale
Centro Interdipartimentale Alma Mater Research Institute for Human-Centered Artificial Intelligence - (Alma AI)
Dipartimento di Fisica e Astronomia "Augusto Righi"

Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León(Spain)

Other Participants:
University Of Cambridge (United Kingdom)
MediSapiens Oy (Finland)
Bayer Ag (Germany)
Bundesinstitut für Arzneimittel und Medizinprodukte (Germany)
Erasmus Universitair Medisch Centrum Rotterdam (Netherlands)
Agencia Espanola De Medicamentos Y Productos Sanitarios (Spain)
Celgene Management Sarl (Switzerland)
Ludwig-Maximilians-Universitat Munchen (Lmu) (Germany)
Gpoh-Gesellschaft Fur Padiatrische Onkologie Und Hamatologie Ggmh (Germany)
Menarini Ricerche s.p.a. (Italy)
Pfizer Limited (United Kingdom)
Masarykova Univerzita (Czech Republic)
The Lymphoma Scientific Association (France)
Mll - Munchner Leukamielabor Gmbh (Germany)
Università degli Studi di TORINO (Italy)
Ospedale Pediatrico Bambino Gesu' (Italy)
Synapse Research Management Partners Sl (Spain)
Groupe Francophone des Myélodysplasies (France)
Fundacio Institut De Recerca Contra La Leucemia Josep Carreras-Ijc (Spain)
Fondazione Italiana Sindromi Mielodisplastiche-FISM onlus (Italy)
European Hematology Association (Netherlands)
Ebmt European Group For Blood And Marrow Transplantation (Netherlands)
Stichting Vu (Netherlands)
Novartis Pharma Ag (Switzerland)
National Institute For Health And Care Excellence-Nice (United Kingdom)
Charite' Universitatsmedizin Berlin (Germany)
Leukanet e.V. (Germany)
European Research Initiative on CLL e.V. (Germany)
Universitaet Ulm (Germany)
ALMA MATER STUDIORUM - Università di Bologna (Italy)
Fondacion Para La Investigacion Del Hospital Universitario La Fe De La Comunidad Valenciana (Hulafe) (Spain)
European LeukemiaNet Foundation-ELN-FOUNDATION (Germany)
Universidad De Navarra (Spain)
GMV Soluciones Globales Internet S.A.U. (Spain)
Genome Research Limited (United Kingdom)
Newcastle University (United Kingdom)
Vib Nucleomics Core (Belgium)
Helsingin Yliopisto (Finland)

Total Eu Contribution: Euro (EUR) 6.715.625,00
Project Duration in months: 36
Start Date: 01/10/2020
End Date: 30/09/2023

Cordis webpage
Project website

Good health and well-being This project contributes to the achievement of the Sustainable Development Goals of the UN 2030 Agenda.

UE flag This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 945406